India opens an anti-dumping case into Chinese glycine, reviving a trade remedy fight over a small-volume amino acid that sits inside food, pharma and the world’s biggest herbicide supply chain
NEW DELHI, 24 September 2026
India’s Directorate General of Trade Remedies has initiated an anti-dumping investigation into imports of glycine originating in or exported from China, opening a case that reaches well beyond the modest tonnage involved and into the pricing of food additives, pharmaceutical excipients and the agrochemical intermediates that feed global glyphosate production.
The investigation was initiated on 22 September 2026 by the DGTR, the trade remedy arm of India’s Ministry of Commerce and Industry. It follows an application by domestic producer Avid Organics, which alleged that dumped imports from China are causing material injury to the Indian industry. The authority will examine data covering the period 2022 to 2025 as its injury window, according to reporting by Daily Excelsior and KNN India.
The action has been logged in the Global Trade Alert database as intervention 160144, classified under the “Anti-dumping” instrument, with a GTA evaluation of “Amber” and a status of “Not yet in force.” The implementing jurisdiction is recorded as India and the affected jurisdiction as China. The “Amber” designation reflects GTA’s convention for measures that are likely to discriminate against foreign commercial interests but whose final form and effect are not yet settled, while “Not yet in force” captures the basic procedural reality of any initiation: a case has been opened, nothing has been decided, and no duty is being collected at the border today.
That distinction matters more than it sounds. An initiation is the start of a process, not its conclusion. Under India’s trade remedy architecture, the DGTR investigates, gathers questionnaire responses from domestic producers, importers, users and foreign exporters, holds an oral hearing, issues disclosure of essential facts and then recommends. The recommendation, if affirmative, travels to the Ministry of Finance, Department of Revenue, which takes the final decision on whether to impose duties, at what rate, and for how long. The Department of Revenue is not obliged to accept a DGTR recommendation, and in recent years it has declined to do so in a meaningful number of cases, often where downstream user industries mounted an effective argument about input costs. Exporters and importers who treat an initiation as a foregone conclusion tend to overpay for hedging; those who treat it as noise tend to be caught out when provisional duties land.
What glycine is, and why a small molecule carries outsized trade weight
Glycine is the simplest amino acid, and among the most versatile industrial chemicals in the fine chemicals category. Its commercial life runs across at least five distinct end markets, and the breadth of that demand base is precisely what makes a trade remedy case on glycine complicated for the authority and consequential for buyers.
In food, glycine functions as a flavour enhancer and sweetener modifier. In pharmaceuticals, it appears both as an active ingredient in certain formulations and, far more commonly, as an excipient and buffering agent, including in solutions where purity specifications are demanding and supplier qualification is slow. In cosmetics it serves as a pH adjuster and conditioning agent; in animal nutrition it enters feed premixes. And in agrochemicals, glycine is a key raw material in the manufacture of glyphosate, the world’s most widely used broad-spectrum herbicide.
That last application is the one that drives volume. Glyphosate production consumes glycine at industrial scale through the glycine route, one of the two dominant synthesis pathways for the herbicide, and the economics of glyphosate manufacturing are unusually sensitive to intermediate input costs because the finished product is a mature, commoditised molecule sold into price-driven agricultural markets. India is a significant glyphosate producer and exporter in its own right, which means a duty on glycine imports would not simply protect one domestic chemical producer against one foreign competitor. It would also change the input cost structure of an Indian export industry that competes directly with Chinese glyphosate producers in third markets.
This is the central tension in the case, and it is the kind of tension that Indian trade remedy proceedings have wrestled with repeatedly in chemicals: the applicant is upstream, a substantial share of the opposition will be downstream, and both sides are Indian.
The applicant and the procedural posture
Avid Organics filed the application that triggered the investigation. The company is a specialty and fine chemicals producer, and its petition alleges that Chinese glycine is entering the Indian market at dumped prices and causing material injury to the domestic industry.
To sustain an affirmative finding, the DGTR will need to establish three things, in line with the WTO Anti-Dumping Agreement and India’s implementing rules under the Customs Tariff Act and the 1995 Anti-Dumping Rules. First, dumping: that the export price to India is below normal value, producing a positive dumping margin. Second, injury: that the domestic industry has suffered material injury or is threatened with it, assessed through volume effects, price effects including undercutting and price suppression, and economic indicators covering capacity utilisation, market share, profitability, cash flow, inventories and employment. Third, causal link: that the dumped imports caused that injury, and that other known factors have not been attributed to them.
The choice of 2022 to 2025 as the injury period is itself informative. A three-year injury window plus a period of investigation is standard practice, and the years selected span a stretch of extraordinary volatility in global chemical markets: the tail of pandemic-era supply disruption and freight inflation, the energy price shock that followed, a sharp destocking cycle across the chemical value chain, and then a prolonged period of Chinese chemical overcapacity pressing on export prices across dozens of product lines. Any injury analysis covering those years has to separate the effect of alleged dumping from the effect of a global chemicals downcycle that hit producers everywhere. Respondent exporters will almost certainly argue precisely that, pointing to the non-attribution requirement.
On normal value, a familiar question will arise. India has historically treated China as a non-market economy for the purposes of certain anti-dumping determinations, permitting the authority to construct normal value using surrogate country data or other methodologies where it concludes that Chinese producers do not operate under market conditions. Chinese respondents have contested that approach for years, and the methodology chosen will have a larger influence on the final dumping margin than almost any other single decision in the case. Exporters that participate fully, submit complete questionnaire responses and seek individual treatment typically fare better than those that stay silent and are assigned a residual rate calculated on facts available.
A product with a long trade remedy history
Glycine is not a newcomer to trade remedy files. It has one of the longer and more tangled histories of any fine chemical.
The United States has run repeated anti-dumping and countervailing duty proceedings covering glycine, with cases at various points reaching imports from China, India, Japan and Thailand. The American proceedings became a case study in circumvention and country-hopping: as duties attached to one origin, trade patterns shifted, and subsequent investigations examined whether Chinese material was being routed or lightly processed through third countries before entering the United States. The relevance for New Delhi is twofold. First, it demonstrates that glycine trade flows are unusually mobile, because the product is a standardised chemical, shipping costs are a modest share of delivered value, and the number of qualified global producers is small enough that redirection is practical. Second, it means India is now acting in a product space where the world’s other major importing jurisdictions have already built duty walls, which itself changes where surplus Chinese tonnage looks for a home.
That second point deserves emphasis. Trade remedies are rarely isolated events. When a major market closes to a given origin, displaced volume seeks alternative destinations, and those destinations see import surges and falling import prices that can look exactly like dumping, because in economic terms it often is. India has been on the receiving end of this dynamic across steel, chemicals and solar components for a decade.
India as a trade remedy power, and the China chemicals caseload
India has been among the most active users of trade remedies in the world, consistently ranking near the top of WTO notification tables for anti-dumping initiations over the past two decades. The DGTR, created in 2018 by merging the earlier Directorate General of Anti-Dumping and Allied Duties with other trade defence functions, was designed to consolidate anti-dumping, countervailing duty and safeguard work under a single roof, and its caseload has remained heavy.
Chemicals dominate that caseload. Organic and inorganic chemicals, intermediates, pigments, rubber chemicals and agrochemical inputs have accounted for a very large share of India’s anti-dumping initiations, and China has been by far the most frequently named origin. The pattern is structural rather than political: China holds dominant global capacity across a wide swathe of commodity and fine chemicals, Indian producers are often mid-sized and capital-constrained relative to Chinese incumbents, and India’s chemical sector has been an explicit target of industrial policy support.
The glycine case arrives in the same week as another DGTR action pointing in the same direction. On 16 September 2026, the authority initiated an anti-circumvention investigation into Chlorinated Polyvinyl Chloride resin, examining allegations that existing duties on China and Korea are being circumvented through Japan, Malaysia and Thailand. The CPVC case is a different instrument addressing a different product, and the two should not be conflated. But read together they illustrate a policy posture: India is not only opening new cases, it is policing the perimeter of the cases it has already decided. For compliance teams, the CPVC action is a reminder that origin engineering and minor-processing strategies attract dedicated scrutiny in India, and that a duty avoided today can become a duty applied retroactively to the circumventing route later.
Stakeholder reactions and positions
Formal reactions at this stage of a case are constrained by procedure rather than by reticence. The DGTR’s initiation notification sets deadlines for interested parties to register and file questionnaire responses, and most participants prefer to make their arguments on the record rather than in the press during the early weeks.
The applicant’s position is on the record by virtue of the petition itself: Avid Organics has alleged that dumped Chinese imports are causing material injury to the domestic industry, and that allegation, supported by prima facie evidence, is what the DGTR found sufficient to justify initiation. Under Indian practice, the authority must satisfy itself that the application is supported by the required proportion of domestic production and that the evidence of dumping, injury and causation meets the threshold for opening an investigation. Initiation therefore signals that the petition cleared a screening test, not that the allegations have been proven.
Trade press coverage, including reporting by Daily Excelsior and KNN India, has framed the case as part of India’s broader effort to shield domestic chemical manufacturers from low-priced Chinese supply, and has highlighted the 2022 to 2025 injury window as the analytical core of the proceeding. KNN India, which reports extensively on the micro, small and medium enterprise sector, has situated the case within the wider set of trade defence actions affecting Indian industrial buyers and sellers.
The Global Trade Alert record, maintained independently of the Indian government, provides the third external marker. Its classification of intervention 160144 as “Amber” and “Not yet in force” gives supply chain managers a neutral, machine-readable reference point for monitoring, which matters for companies running automated trade compliance screening across hundreds of product lines.
Downstream user reaction is the piece to watch. Indian glyphosate formulators and technical-grade producers, pharmaceutical manufacturers who have qualified specific glycine grades and suppliers, and food ingredient companies all have standing to participate as interested parties. In Indian chemical cases of this shape, user industry associations frequently intervene to argue that duties on an intermediate raise costs for a larger downstream industry, reduce export competitiveness, and in the worst configuration transfer market share from Indian downstream producers to foreign finished-product suppliers who still buy their inputs at world prices. Whether that argument gains traction here will depend substantially on the demonstrated capacity of Indian glycine production relative to Indian consumption.
Economic impact analysis
The immediate economic question is one of pass-through. Glycine is an input, and the cost effect of any duty is determined by three variables: the share of glycine in the downstream cost stack, the availability of non-Chinese alternative supply at comparable specification and price, and the ability of downstream producers to pass cost increases to their own customers.
For glyphosate, glycine is a material input by both weight and value in the glycine synthesis route, and glyphosate itself is sold into a market where price competition is intense and buyers are agricultural distributors with limited tolerance for premium pricing. Pass-through capacity is therefore weak. If duties are imposed at a meaningful rate and alternative supply is thin, Indian glyphosate producers face margin compression rather than a simple price adjustment. That is the scenario user industry representatives will describe to the authority.
For pharmaceutical applications, the calculus differs. Glycine is typically a small share of formulation cost, but supplier qualification is regulated, documented and slow. Switching sources is not a procurement decision made in a week; it involves specification matching, stability data, regulatory filings and in some cases customer notification. The cost of a duty in pharma is less about the percentage added to the input price and more about the disruption risk if a qualified supplier becomes uneconomic and a replacement has to be qualified under time pressure.
For food and feed applications, substitution is easier and the cost share is small, so the economic effect is more modest and more readily absorbed.
Aggregated across those channels, the plausible outcome of an affirmative determination is a moderate increase in Indian domestic glycine prices, improved capacity utilisation and profitability for the domestic producer, some redirection of imports toward non-Chinese origins, and a squeeze on downstream agrochemical margins that is concentrated rather than diffuse. The distributional politics are typical of intermediate chemical cases: benefits accrue to a small number of identifiable producers, costs are spread across a larger and more fragmented downstream base.
There is also a second-order effect worth naming. Duties on intermediates can accelerate domestic capacity investment where the protected margin is credible and durable, an outcome India’s chemical policy framework has explicitly sought. The counter-risk is that protection sustains a high-cost domestic base without generating scale.
Implications for global importers, exporters and supply chains
For Chinese glycine exporters, the operational priority is participation. Non-participating exporters in Indian proceedings are routinely assigned residual duty rates derived from facts available, and those rates are typically the highest in the determination. Exporters seeking individual margins need to file complete, verifiable questionnaire responses within the deadlines set in the initiation notification, and should expect scrutiny of cost allocation, related-party transactions and export price adjustments.
For Indian importers and traders, the first task is exposure mapping: contracted volumes, shipment timing, and the contractual allocation of duty risk. Provisional duties in Indian practice can be imposed after a preliminary finding and apply prospectively from the date of the notification, which means goods on the water at the time of a preliminary determination may or may not be affected depending on entry timing. Contracts that are silent on the allocation of newly imposed trade remedy duties are the single most common source of commercial dispute in these situations. Importers should be reviewing force majeure, change-in-law and price adjustment clauses now, not after a preliminary finding.
For global producers outside China, the case is an opportunity with a caveat. Japanese, Southeast Asian and other non-Chinese glycine suppliers stand to gain share in India if duties attach to Chinese origin. The caveat is India’s demonstrated willingness to open anti-circumvention proceedings, as the CPVC case illustrates. Suppliers whose Indian volumes suddenly expand while their upstream sourcing shifts toward Chinese intermediates should expect that pattern to be noticed. Substantial transformation and origin documentation need to be defensible on the facts, not merely on paper.
For multinational buyers with global procurement, the broader lesson concerns the cumulative geography of glycine trade defence. With the United States having maintained duties across multiple origins and India now examining Chinese supply, the number of large open markets for unencumbered Chinese glycine is narrowing. That concentrates displaced volume into remaining destinations and raises the probability of further initiations elsewhere. Procurement teams running multi-year supply agreements for glycine should be pricing regulatory risk explicitly rather than assuming continuity of current landed costs.
Supply chain resilience planning should also account for the grade distinction. Technical-grade glycine for agrochemical use, food-grade glycine and pharmaceutical-grade glycine are not freely interchangeable, and any duty scope defined broadly at the product level will affect all three while alternative supply depth varies sharply among them. Interested parties often argue for product scope exclusions on exactly this basis, and scope arguments are far more effective when filed early with technical evidence than when raised after a preliminary finding.
Outlook
The realistic timeline runs as follows. Interested parties register and file responses over the coming weeks. The DGTR may issue a preliminary finding and recommend provisional duties, though it is not required to do so and in many cases proceeds directly toward a final determination. Indian anti-dumping investigations are ordinarily to be completed within twelve months of initiation, with provision for extension, so a final recommendation in the second half of 2027 would be within normal expectations, with a preliminary finding possible considerably earlier. Any affirmative recommendation then requires acceptance by the Department of Revenue and a customs notification before duties are collected. Definitive duties, where imposed, typically run for five years subject to sunset review.
Three variables will shape the outcome more than the rest. The first is the normal value methodology applied to Chinese exporters, which will largely set the dumping margin range. The second is the strength of the non-attribution analysis, given that the 2022 to 2025 injury window overlaps a global chemicals downcycle that depressed prices and margins independently of any dumping. The third is the weight the authority and, ultimately, the Department of Revenue assign to downstream user interest, particularly from the glyphosate sector, whose export competitiveness is directly exposed.
For now, the position is procedurally clear and commercially uncertain: a case is open, no duty is in force, and the parties that engage early with evidence will have disproportionate influence over what the final measure looks like. Glycine is a small molecule with a long trade remedy record, and this case suggests that record has another chapter to run.